Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF

Phase 1

• Conditions: Moyamoya disease; Moyamoya disease, indirect revascularization, Granulocyte-Colony Stimulating Factor; D009072

• Registration Number: JPRN-jRCTs071220048
• Lead Sponsor: Morioka Motohiro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

1.Moyamoya disease requiring direct/indirect revascularization.
2.Age:20-60 years old.
3.Obtain informed consent by the document.

Exclusion Criteria

1.Splenomegaly or splenic lesions on abdominal echo.
2.Leukocytosis more than 15000/mm3
3.Past histries of symptomatic intracranial hemorrhage, bleeding tendency or coagulating disorders.
4.Hyper reactivity to G-CSF.
5.Congestive heart failure or uncontrollable angina.
6.Thrombocytopenia(less than 140000/mm3)
7.Liver dysfunction(AST(GOT),ALT(GPT) more than 100 IU/L)
8.Renal dysfunction (creatinine 1.5mg/dl and more)
9.Difficult to continue this trial due to social problems, etc.
10.Join other clinical trials.
11.Inappropriate to enroll in this trial by the judgment of the doctor.

Study & Design

• Study Type: Interventional
• Study Design: Not specified